Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells-Reference-Cited by-同舟云学术

Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells

Published:2021-07 Issue:4 Volume:22 Page:e487-e497
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Owen Dwight H.^ORCID,Benner Brooke,Pilcher Carly,Good Logan^ORCID,Savardekar Himanshu^ORCID,Norman Ruthann,Ghattas Christian,Shah Manisha,Konda Bhavana,Verschraegen Claire F.^ORCID,Wesolowski Robert,Behbehani Gregory K.^ORCID,Carson William E.,Otterson Gregory A.

Funder

BMS

BMS-OSU collaborative research grant

Clinical Faculty Investigators

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference50 articles.

1. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;Horn;N Engl J Med,2018

2. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer;Owonikoko;J Thorac Oncol,2012

3. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial;Antonia;Lancet Oncol,2016